期刊文献+

HRG-1基因在膀胱癌和正常膀胱组织中的表达

Expression of HRG-1 gene in carcinoma of urinary bladder and normal bladder tissues
下载PDF
导出
摘要 目的观察HRG-1基因在膀胱正常组织和膀胱癌组织中的表达,探讨HRG-1基因表达与膀胱肿瘤病理分级和临床分期的关系。方法应用免疫组化SP法检测63例膀胱癌和28例膀胱正常组织石蜡标本中HRG-1表达情况,并进行相关临床病理分析。结果在正常膀胱组织和膀胱癌组织中HRG-1表达有显著性差异(P<0.05);HRG-1的阳性表达与膀胱癌病例分级、临床分期之间有显著性差异(P<0.05)。结论 HRG-1基因在膀胱癌组织中表达水平显著提高,提示该基因可能对膀胱肿瘤病理分级和临床分期有一定的指导意义。 Objective To observe HRG-1 gene expression in carcinoma of urinary bladder and normal urinary bladder tissues,and to explore the relationship between HRG-1 gene expression and bladder tumor pathologic stage and the clinical stages.Methods Immunohistochemisty was used to detect the expression of HRG-1 in 63 cases of bladder cancer and 28 normal bladder tissues.Results HRG-1 gene expression had significant differences between bladder cancer and normal bladder tissues(P0.05);HRG-1 gene positive expression had marked differences between the pathological grades and clinical stages of bladder cancer(P0.05).Conclusions The high expression of HRG-1 gene may play an important role in bladder cancer,and may served as valuable indicators of the pathological grades and clinical stages of bladder cancer.
出处 《现代泌尿外科杂志》 CAS 2011年第2期145-147,共3页 Journal of Modern Urology
基金 国家自然科学基金(No.30271302)
关键词 膀胱肿瘤 人类血红素敏感基因1 病理分级 临床分期 carcinoma of urinary bladder HRG-1 pathological grades clinical stages
  • 相关文献

参考文献2

二级参考文献35

  • 1Jemal A,Clegg LX,Ward E,et al.Annual Report to the Nation on the Status of Cancer,1975-2001,with a Special Feature Regarding Survival[J].Cancer,2004,101:3-27.
  • 2Laudadio J,Keane TE,Reeves HM,et al.Fluorescence in situ hybridization for detecting transitional cell carcinoma:implications for clinical practice[J].BIU Int,2005,96:1280-1285.
  • 3Kipp BR,Karnes RJ,Brankley SM,et al.Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization[J].J Urol,2005,173:401-404.
  • 4Bollmann M,Heller H,Bankfalvi A.Quantitative molecular urinary cytology by fluorescence in situ hybridization:a tool for tailoring surveillance of patients with superficial bladder cancer?[J].BJU Int,2005,95:1219-1225.
  • 5Quek ML,Sanderson K,Daneshmand S,et al.New molecular markers for bladder cancer detection[J].Curr Opin Urol,2004,14:259-264.
  • 6Miller T,Beausang L,Winchell L,et al.Detection of nuclear matrix proteins in serum from cancer patient[J].Cancer Res,1992,52:422-427.
  • 7Zippe C,Pandrangi L,Agarwal A.NMP22 is a sensitive cost effect test in patients at risk for bladder cancer[J].J Urol,1999,161:62-65.
  • 8Miyanaga N,Akaza H,Tsukamoto T,et al.Urinary nuclear matrix protein (NMP22) as a marker for screening urothelial cancer in patients with microscopic hematuria[J].Int J Urol,1998,159:243-247.
  • 9Carpinito GA,Stadler WM,Briggman JV,et al.Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract[J].J Urol,1998,159:245-248.
  • 10Dey P.Urinary markers of bladder carcinoma[J].Clin Chim Acta,2004,340:57-65.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部